Condition: Leukemia, Myeloid, Acute(AML) · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Myelodysplastic Syndromes (MDS) · Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic
Adult patients with refractory or relapsed CD123+ hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, or blastic plasmocytoid dentritic cell neoplasm will be recruited in the trial. CART123 cells will be manufatured from blood of each patient. During the production of CAR123 cells, patients may receive appropriate bridging therapy. After cells are produced, participants will undergo a single course of lymphodepleting chemotherapy and receive a single dose of CAR123 T cells. The trial will establish the recommended dose for further studies, either the Maximum Tolerated Dose (MTD) or Maximum Feasible Dose (MFD). Patients must be eligible for hematopoietic stem cell transplantation in order to participate in the trial.
This description comes directly from the study's public registry record.
Petr Lesny, MD, PhD · +420 221 977 629 · Petr.Lesny@uhkt.cz
Jan Vydra, MD, PhD · +420 221 977 290 · jan.vydra@uhkt.cz
Always discuss trial participation with your own doctor first.
| Ustav hematologie a krevni transfuze / Institute of Hematology and Blood Transfusion | Prague, Czechia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06765876